NCT04142918 (DIAMOND-1) is a clinical trial of Immunostaining in Oral Mucosa, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT04142918?

NCT04142918 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT04142918?

Interventions in NCT04142918: Immunostaining.

What condition does NCT04142918 study?

NCT04142918 studies Oral Mucosa.

Is NCT04142918 still recruiting?

NCT04142918 is currently status unknown. Last updated 25 March 2020.

Last reviewed 2020-03-25 · How we verify

NCT04142918: DIAMOND-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Markers of Neuropathic Odontalgia

Status unknown Last updated 25 March 2020

What this trial tests

trial testing Immunostaining in Oral Mucosa in 45 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 December 2020

1 March 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	45
Start date	1 June 2020
Primary completion	1 December 2020
Estimated completion	1 March 2021
Sites	1 location across France

Drugs / interventions tested

Immunostaining

Conditions studied

Oral Mucosa — all drugs for Oral Mucosa →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Oral Mucosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The DIAMOND study aims to investigate the presence and diagnostic relevance of potential biomarkers of the blood-nerve barrier disruption as surrogate markers of painful post-traumatic trigeminal neuropathic pain in patients presenting with neuropathic odontalgia. The first part of the study explores the proof-of-concept and technical feasibility of intra-epithelial nerve fiber immunostaining in gingival/oral mucosa biopsies and the potential presence of these biomarkers in healthy patients (baseline condition).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04142918 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 25 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing